Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report

We report the case of a 39-year-old woman with primary breast cancer and associated synchronous bone metastases, who experienced a disease response of 12 years with hormonal therapy as maintenance after first line chemotherapy, with a good toxicity profile. Diagnosis: The patient was diagnosed with estrogen receptor + human epidermal growth factor receptor 2 (HER2)− metastatic breast cancer with synchronous bone metastases. Interventions: This patient was treated with chemotherapy for 6 cycles as a first-line therapy following by endocrine treatment given as a maintenance therapy. Outcomes: Our patient experienced a progression-free survival>12 years with an exceptionally good quality of life. Lessons: Our anecdotal experience highlights the existence of exceptional responders among patients with hormone receptor-positive metastatic breast cancer, who achieve clinical remission and durable disease control with endocrine therapy. Being able to identify these patients could help in the selection of the best treatment option among the many available.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research